The Retinoids and Cancer Prevention Mechanisms
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Carcinogenesis is a multistep process that converts normal cells into malignant cells. Once transformed, malignant cells acquire the ability to invade and metastasize, leading to clinically evident disease. During this continuum from normal to metastatic cells, carcinogenic steps can be arrested or reversed through pharmacological treatments, known as cancer chemoprevention. Chemoprevention strategies represent therapeutic interventions at early stages of carcinogenesis, before the onset of invasive cancer. Effective chemoprevention should reduce or avoid the clinical consequences of overt malignancies by treating early neoplastic lesions before development of clinically apparent signs or symptoms. Preclinical, clinical, and epidemiological data provide considerable support for cancer chemoprevention as an attractive therapeutic strategy. This clinical approach was validated in the recent tamoxifen randomized trial, demonstrating that a selective estrogen receptor modulator reduces the risk of breast cancer in women at high risk for this malignancy. Derivatives of vitamin A, the retinoids, have reported activity in treating specific premalignant lesions and reducing incidence of second primary tumors in patients with prior head and neck, lung or liver cancers. Whether the retinoids will prevent primary cancers at these sites is not yet known. Notably, a carotenoid (β-carotene) was shown as inactive in primary prevention of lung cancers in high-risk individuals. This underscores the need for relevant in vitro models to identify pathways signaling chemopreventive effects. These models should assess the activity of candidate chemoprevention agents before the conduct of large and costly prevention trials. An improved understanding of cancer prevention mechanisms should aid in the discovery of new therapeutic targets and chemoprevention agents. Ideally, these agents should have tolerable clinical toxicities suitable for chronic administration to individuals at high risk for developing primary or second cancers. This article reviews what is now known from clinical and preclinical studies about the retinoids as cancer prevention agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1994) · New England Journal of Medicine · doi:10.1056/nejm199404143301501 · Cited by 4,737
Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J., Cullen, M. R., Glass, A., Keogh, J. P., Meyskens, F. L., Valanis, B., Williams, J. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605023341802 · Cited by 3,638 · cited 2×
“These effects are consistent with prior reports of inactivity of carotenoids in lung cancer prevention [ 28-30 ].”
ResultA decade of molecular biology of retinoic acid receptors
Chambon, P. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.9.8801176 · Cited by 2,889 · cited 2×
“Targeting of individual retinoid receptors reveal receptor-specific developmental and differentiation defects [32, 42 , 45, 46].”
BackgroundHennekens, C. H., Buring, J. E., Manson, J. E., Stampfer, M., Rosner, B., Cook, N. R., Belanger, C., LaMotte, F., Gaziano, J. M., Ridker, P. M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605023341801 · Cited by 2,397 · cited 2×
“These effects are consistent with prior reports of inactivity of carotenoids in lung cancer prevention [ 28-30 ].”
ResultA human retinoic acid receptor which belongs to the family of nuclear receptors
Petkovich, M., Brand, N. J., Krust, A., & Chambon, P. (1987) · Nature · doi:10.1038/330444a0 · Cited by 2,214
Identification of a receptor for the morphogen retinoic acid
Giguere, V., Ong, E. S., Segui, P., & Evans, R. M. (1987) · Nature · doi:10.1038/330624a0 · Cited by 1,965
9-cis retinoic acid is a high affinity ligand for the retinoid X receptor
Heyman, R. A., Mangelsdorf, D. J., Dyck, J. A., Stein, R. B., Eichele, G., Evans, R. M., & Thaller, C. (1992) · Cell · doi:10.1016/0092-8674(92)90479-v · Cited by 1,780 · cited 1×
“It is known that 9-cis-retinoic acid is a bifunctional retinoid activating both RAR and RXR pathways, while alltrans retinoic acid (RA) activates only the RAR pathway [ 52 , 53].”
BackgroundA unified nomenclature system for the nuclear receptor superfamily
(1999) · Cell · doi:10.1016/s0092-8674(00)80726-6 · Cited by 1,208
Muindi, J., Frankel, Sr., Miller, W. J., Jakubowski, A., Scheinberg, D., Young, C., Dmitrovsky, E., & Warrell, R. J. (1992) · Blood · doi:10.1182/blood.v79.2.299.299 · Cited by 314
Self-citationMeyskens, F. L., Surwit, E., Moon, T. E., Childers, J. M., Davis, J. R., Dorr, R. T., Johnson, C. S., & Alberts, D. S. (1994) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/86.7.539 · Cited by 263
Cited by
From carrot to clinic: an overview of the retinoic acid signaling pathway
Theodosiou, M., Laudet, V., & Schubert, M. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0268-z · Cited by 328
Retinoids in cancer therapy and chemoprevention: Promise meets resistance
Freemantle, S. J., Spinella, M. J., & Dmitrovsky, E. (2003) · Oncogene · doi:10.1038/sj.onc.1206936 · Cited by 312
Self-citationLópez-Carballo, G., Moreno, L., Masiá, S., Pérez, P., & Barettino, D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201869200 · Cited by 301
Budhu, A. S., & Noy, N. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2632-2641.2002 · Cited by 296
Bexarotene: A promising anticancer agent
Qu, L., & Tang, X. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1140-4 · Cited by 78
Metadata
- Authors
- Dragnev, K. H., Rigas, J. R., & Dmitrovsky, E.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-10-01
- Volume
- 5
- Issue
- 5
- Pages
- 361-368
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2165189118
- Cited by
- 112
- References
- 12
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Retinoids and Cancer Prevention Mechanisms. https://app.cochat.ai/papers/10.1634/theoncologist.5-5-361
- The paper
- Dragnev, K. H., Rigas, J. R., & Dmitrovsky, E. (2000). The Retinoids and Cancer Prevention Mechanisms. The Oncologist. https://doi.org/10.1634/theoncologist.5-5-361
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.